Isoxazoline compound and pesticide
    11.
    发明授权
    Isoxazoline compound and pesticide 有权
    异恶唑啉化合物和农药

    公开(公告)号:US08242283B2

    公开(公告)日:2012-08-14

    申请号:US13073463

    申请日:2011-03-28

    IPC分类号: C07D261/02

    摘要: A pesticide, particularly an insecticide or an acaricide, including a substituted isoxazoline compound of formula (1) or a salt thereof: wherein A1, A2 and A3 independently of one another are carbon atom or nitrogen atom, G is benzene ring, etc., L is —N(R2c)—, or —CH(R2a)N(R2c)—, etc., X is halogen atom, C1-C6 haloalkyl, etc., Y is halogen atom, C1-C6alkyl, etc., R1 is —C(O)R1a, —C(O)OR1a, —C(O)NHR1a, etc., R2 is hydrogen atom, C1-C6haloalkyl, —C1-C4alkoxy C1-C4alkyl, cyano C1-C6alkyl, C3-C6alkenyl, C3-C6alkynyl, —C(O)R15, —C(O)OR15, etc., R3 is C1-C6haloalkyl, etc., m is an integer of 0 to 5, n is an integer of 0 to 4. The pesticide containing these compounds.

    摘要翻译: 一种杀虫剂,特别是杀虫剂或杀螨剂,其包括式(1)的取代的异恶唑啉化合物或其盐:其中A1,A2和A3彼此独立地是碳原子或氮原子,G是苯环等, L是-N(R2c) - 或-CH(R2a)N(R2c) - 等,X是卤素原子,C1-C6卤代烷基等,Y是卤素原子,C1-C6烷基等,R1 是-C(O)R 1a,-C(O)OR 1 a,-C(O)NHR 1a等,R 2是氢原子,C 1 -C 6卤代烷基,-C 1 -C 4烷氧基C 1 -C 4烷基,氰基C 1 -C 6烷基,C 3 -C 6烯基 ,C 3 -C 6炔基,-C(O)R 15,-C(O)OR 15等,R 3为C 1 -C 6卤代烷基等,m为0〜5的整数,n为0〜4的整数。 含有这些化合物的农药。

    Organic compounds
    14.
    发明授权
    Organic compounds 失效
    有机化合物

    公开(公告)号:US07786155B2

    公开(公告)日:2010-08-31

    申请号:US12251650

    申请日:2008-10-15

    摘要: The invention relates to compound of the formula I wherein the substituents are as defined in the specification; in free base form or in acid addition salt form; to its preparation, to its use as medicament and to medicaments comprising it.

    摘要翻译: 本发明涉及式I化合物,其中取代基如说明书中所定义; 游离碱形式或酸加成盐形式; 作为其制备,用作药物和包含它的药物。

    NOVEL PHENYL-ISOXAZOL-3-OL DERIVATIVE
    16.
    发明申请
    NOVEL PHENYL-ISOXAZOL-3-OL DERIVATIVE 有权
    新型PHENYL-ISOXAZOL-3-OL DERIVATIVE

    公开(公告)号:US20100130559A1

    公开(公告)日:2010-05-27

    申请号:US12516025

    申请日:2007-11-29

    摘要: The present invention relates to a compound represented by formula (I), which has a GPR120 agonist action and thus is useful for treatment of diabetes mellitus or hyperlipidemia, or a pharmaceutically acceptable salt thereof. In the formula, (AA) represents a phenyl or the like, which may be substituted with a lower alkoxy group or the like; (BB) represents a divalent group or the like, derived by removal of two hydrogen atoms from a benzene which may be substituted with a halogen atom or the like; X represents a spacer having a main chain composed of 1-8 carbon atoms wherein 1-3 carbon atoms in the main chain may be substituted with an oxygen atom or the like; and Y represents a hydrogen atom or the like.

    摘要翻译: 本发明涉及由式(I)表示的化合物,其具有GPR120激动剂作用,因此可用于治疗糖尿病或高脂血症或其药学上可接受的盐。 式中,(AA)表示可以被低级烷氧基等取代的苯基等, (BB)表示通过从可以被卤素原子等取代的苯中除去两个氢原子得到的二价基团等; X表示具有由1-8个碳原子构成的主链的间隔基,其中主链中的1-3个碳原子可以被氧原子等取代; Y表示氢原子等。

    Isoxazoline compounds having MIF antagonist activity
    17.
    发明授权
    Isoxazoline compounds having MIF antagonist activity 失效
    具有MIF拮抗剂活性的异恶唑啉化合物

    公开(公告)号:US07662843B2

    公开(公告)日:2010-02-16

    申请号:US10828240

    申请日:2004-04-21

    申请人: Yousef Al-Abed

    发明人: Yousef Al-Abed

    IPC分类号: A01N43/80 C07D261/02

    CPC分类号: A61K31/421 C07D261/04

    摘要: Methods of use and pharmaceutical compositions for a genus of low molecular weight compounds comprising optionally substituted isoxazoline ring systems that act as inhibitors of MIF (macrophage migration inhibitory factor) are disclosed. Specifically, the compounds are useful for treating a variety of diseases involving inflammatory activity or pro-inflammatory cytokine responses, such as autoimmune diseases (including rheumatiod arthritis, insulin-dependent diabetes, multiple sclerosis, graft versus host disease, lupus syndromes), asthma, arthritis, ARDS, psoriasis, interleukin-2 toxicity, proliferative vascular disease, and various forms of sepsis and septic shock, and other conditions characterized by underlying MIF responses including, for instance, tumor growth and neovascularization (angiogenesis).

    摘要翻译: 公开了用作低分子量化合物的药物组合物的方法,其包含用作MIF抑制剂(巨噬细胞迁移抑制因子)的任选取代的异恶唑啉环体系。 具体地说,该化合物可用于治疗涉及炎症活性或促炎细胞因子应答的各种疾病,例如自身免疫性疾病(包括风湿性关节炎,胰岛素依赖性糖尿病,多发性硬化,移植物抗宿主病,狼疮综合征),哮喘, 关节炎,ARDS,牛皮癣,白细胞介素-2毒性,增殖性血管疾病和各种形式的败血症和败血性休克,以及其他基本MIF反应特征的病症,包括例如肿瘤生长和新生血管形成(血管生成)。